Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
01 Feb 2024
Historique:
received: 01 06 2023
medline: 1 2 2024
pubmed: 1 2 2024
entrez: 1 2 2024
Statut: aheadofprint

Résumé

The patterns of low risk myelodysplastic syndrome (MDS) progression, and the clinical and molecular features of those patterns are not well described. We divided our low risk (LR) MDS patients (n=1914) into 4 cohorts: 1) Patients who remained LR-MDS (LR-LR; n=1300; 68%), 2) Patients who progressed from LR to HR MDS (LR-HR) without AML transformation (n=317; 16.5%), 3) Patients who progressed from LR to HR MDS and then AML (LR-HR-AML; n=124; 6.5%), 4) Patients who progressed from LR MDS to AML directly (LR-AML; n=173; 9%). Risk factors for progression included male gender, low absolute neutrophil count (ANC), low platelet count, high bone marrow (BM) blasts, ferritin >1000 mcg/L, albumin.

Identifiants

pubmed: 38299605
doi: 10.3324/haematol.2023.283661
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Akriti G Jain (AG)

Associate Staff, Leukemia Division, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Jaina9@ccf.org.

Somedeb Ball (S)

Assistant Professor of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN.

Luis Aguirre (L)

Leukemia Fellow, Dana-Farber Cancer Institute, Boston, MA.

Najla Al Ali (N)

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

David Kaldas (D)

Internal Medicine Resident, University of South Florida, Tampa, FL.

Sara Tinsley-Vance (S)

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Andrew Kuykendall (A)

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Onyee Chan (O)

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Kendra Sweet (K)

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Jeffrey E Lancet (JE)

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Eric Padron (E)

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

David A Sallman (DA)

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Rami Komrokji (R)

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Rami.Komrokji@moffitt.org.

Classifications MeSH